Rigel Pharmaceuticals (RIGL) News Today $20.09 -0.74 (-3.55%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$19.96 -0.13 (-0.62%) As of 02/21/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above 200 Day Moving Average - Should You Sell?February 18, 2025 | americanbankingnews.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above Two Hundred Day Moving Average - What's Next?Rigel Pharmaceuticals (NASDAQ:RIGL) Share Price Crosses Above 200-Day Moving Average - Time to Sell?February 18, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Large Growth in Short InterestRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 560,700 shares, a growth of 22.7% from the January 15th total of 456,900 shares. Based on an average trading volume of 301,900 shares, the days-to-cover ratio is currently 1.9 days. Currently, 3.3% of the company's shares are sold short.February 16, 2025 | marketbeat.comARMISTICE CAPITAL, LLC Reduces Stake in Rigel Pharmaceuticals IncFebruary 15, 2025 | gurufocus.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CFO Sells $42,593.12 in StockFebruary 7, 2025 | insidertrades.comRigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stockFebruary 7, 2025 | msn.comRigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075February 6, 2025 | msn.comRigel Pharmaceuticals exec sells shares for $83,836February 6, 2025 | msn.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CFO Sells $42,593.12 in StockRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) CFO Dean L. Schorno sold 2,036 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total value of $42,593.12. Following the completion of the sale, the chief financial officer now directly owns 58,969 shares of the company's stock, valued at $1,233,631.48. The trade was a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.February 6, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EVP David A. Santos Sells 2,125 SharesRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) EVP David A. Santos sold 2,125 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total value of $44,455.00. Following the sale, the executive vice president now owns 53,500 shares in the company, valued at approximately $1,119,220. The trade was a 3.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.February 6, 2025 | marketbeat.comInsider Selling: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CEO Sells 4,952 Shares of StockRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) CEO Raul R. Rodriguez sold 4,952 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total value of $103,595.84. Following the sale, the chief executive officer now owns 243,854 shares of the company's stock, valued at approximately $5,101,425.68. This trade represents a 1.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.February 6, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Large Drop in Short InterestRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 456,900 shares, a decline of 43.4% from the December 31st total of 807,500 shares. Currently, 2.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 269,100 shares, the short-interest ratio is presently 1.7 days.February 3, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from AnalystsShares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been given an average recommendation of "Hold" by the five brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have given a buJanuary 28, 2025 | marketbeat.comBuy Rating for Rigel: Promising Clinical Developments and Strong Commercial PerformanceJanuary 22, 2025 | markets.businessinsider.comRigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinibJanuary 22, 2025 | markets.businessinsider.comRigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $57.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday.January 22, 2025 | marketbeat.comRigel's fostamatinib enters Phase 1 trial for sickle cell treatmentJanuary 22, 2025 | msn.comRigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell DiseaseJanuary 22, 2025 | prnewswire.comCantor Fitzgerald Forecasts RIGL FY2025 EarningsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Rigel Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biotechnoJanuary 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 30,987 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Assenagon Asset Management S.A. cut its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 7.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 410,778 shares of the biotechnoJanuary 20, 2025 | marketbeat.comBarclays PLC Has $442,000 Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Barclays PLC increased its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 158.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,345 shares of the biotechnology company's stock after purchaJanuary 19, 2025 | marketbeat.comShort Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1%Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 807,500 shares, an increase of 27.1% from the December 15th total of 635,400 shares. Approximately 4.7% of the company's stock are sold short. Based on an average daily trading volume, of 243,900 shares, the days-to-cover ratio is currently 3.3 days.January 17, 2025 | marketbeat.comHC Wainwright Has Bullish Estimate for RIGL Q4 EarningsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Research analysts at HC Wainwright boosted their Q4 2024 earnings estimates for Rigel Pharmaceuticals in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company wJanuary 17, 2025 | marketbeat.comCantor Fitzgerald Analysts Boost Earnings Estimates for RIGLRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2024 earnings estimates for Rigel Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 14th. Cantor Fitzgerald analyst K. Kluska now forecasts thaJanuary 16, 2025 | marketbeat.comStrong Commercial Performance and Promising Pipeline Drive Rigel’s Buy RatingJanuary 14, 2025 | markets.businessinsider.comRigel Pharmaceuticals sees Q4 revenue $57.6M, consensus $47.42MJanuary 14, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Rigel Pharmaceuticals (NASDAQ:RIGL)HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research note on Tuesday.January 14, 2025 | marketbeat.comRigel Pharmaceuticals Reports Preliminary Q4 Results; Issues 2025 OutlookJanuary 13, 2025 | markets.businessinsider.comRigel Provides Business Update and 2025 OutlookJanuary 13, 2025 | prnewswire.comRigel announces R289 granted Orphan Drug designation by FDA for MDSJanuary 10, 2025 | markets.businessinsider.comRigel Pharmaceuticals, Inc.: Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDSJanuary 9, 2025 | finanznachrichten.deRigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289January 9, 2025 | marketwatch.comRigel Pharma: FDA Grants Orphan Drug Designation To R289 - Quick FactsJanuary 9, 2025 | markets.businessinsider.comRigel Announces R289 Granted Orphan Drug Designation by the FDA for MDSJanuary 9, 2025 | prnewswire.comRigel to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | prnewswire.comJane Street Group LLC Sells 80,271 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Jane Street Group LLC cut its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 75.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,589 shares of the biotechnology company'January 8, 2025 | marketbeat.comRigel granted orphan status for myelodysplastic syndromes treatmentJanuary 7, 2025 | markets.businessinsider.comRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)January 3, 2025 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from BrokeragesRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy reJanuary 3, 2025 | marketbeat.comRigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline AgentsDecember 30, 2024 | seekingalpha.comRigel Pharmaceuticals (NASDAQ:RIGL) Stock Crosses Above 200 Day Moving Average - Here's What HappenedRigel Pharmaceuticals (NASDAQ:RIGL) Share Price Crosses Above 200 Day Moving Average - What's Next?December 26, 2024 | marketbeat.comShould You Buy the Dip on Rigel Pharmaceuticals (RIGL)?December 16, 2024 | wallstreetzen.comRecent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 yearDecember 12, 2024 | finance.yahoo.comRigel Pharmaceuticals price target raised to $25 from $15 at Cantor FitzgeraldDecember 11, 2024 | markets.businessinsider.comRigel Pharmaceuticals price target lowered to $20 from $27 at B. RileyDecember 11, 2024 | markets.businessinsider.comRigel Pharmaceuticals announces initial data from Phase 1b study of R289December 10, 2024 | markets.businessinsider.comRigel Pharmaceuticals (NASDAQ:RIGL) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research note on Tuesday.December 10, 2024 | marketbeat.comRigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionDecember 9, 2024 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from AnalystsShares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been given an average rating of "Hold" by the five brokerages that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy ratinDecember 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 60,913 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Jacobs Levy Equity Management Inc. reduced its stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 25.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 177,340 shares of the biotechnology company's stock after selling 60December 8, 2024 | marketbeat.com Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address RIGL Media Mentions By Week RIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RIGL News Sentiment▼0.960.60▲Average Medical News Sentiment RIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RIGL Articles This Week▼43▲RIGL Articles Average Week Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Celldex Therapeutics News MannKind News Myriad Genetics News Novavax News Innoviva News OPKO Health News Emergent BioSolutions News Codexis News XOMA News Ironwood Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RIGL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RIGL Stock Alerts